Q-omics provides the consensus-scored CLIP4 profile across patient tissues and cancer cell-line models. CLIP4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CLIP4 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, CLIP4 RNA expression shows 20,071 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, COAD, and UVM as cancer lineages where CLIP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLIP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLIP4 survival associations across molecular data types. CLIP4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLIP4 RNA expression–survival associations across cancer types. High CLIP4 expression shows unfavorable associations in KIRP, LAML, KIRC and UCEC, but favorable associations in SKCM and MESO. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CLIP4 RNA expression.
This table summarizes CLIP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CLIP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLIP4 shows lower tumor expression in COAD, BLCA, KIRC, BRCA and UCEC and higher tumor expression in CHOL. The COAD box plot shows higher CLIP4 RNA expression in normal versus tumor tissue (log2 FC = −1.232, t-test p < 0.001).
This table shows molecular features associated with CLIP4 in patient tissues and cancer cell lines. In patient samples, CLIP4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CLIP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
